NAN – Morgans rates the stock as Add
The target price falls to $4.86 from $5.43, the Add rating is retained after a significant share price fall.
Read MoreThe target price falls to $4.86 from $5.43, the Add rating is retained after a significant share price fall.
Read MoreThe broker maintains its Add rating and $5.43 target price.
Read MoreThe broker lowers forecasts, mainly in FY21, to reflect an exchange rate adjustment to consumables. The target price have been revised down to $6.57 from $6.69.
Read MoreEven though the August profit release may cause some price weakness, Morgans prefers to get in early with a upgrade to Add, given the share price is -10% below the broker’s target price of $6.92. The post-result weakness may arise from limited hospital access in the last few months.
Read MoreShare price of Nanosonics has been relatively stable during this period of pandemic-generated volatility, observes Morgans.
Read MoreSam Twidale, Portfolio Manager for the DNR Capital Australian Emerging Companies Fund, explains why he believes recent volatility in equity markets has provided some excellent opportunities in the smaller cap sector.
Read MoreAndrew Page of Strawman.com highlights three Australian companies with net cash and zero debt that should offer safe harbour at this time.
Read MoreDNR Capital Portfolio Manager Sam Twidale last discussed Nanosonics (ASX:NAN) back in April 2019. Since that time the share price has rallied strongly from the mid $4 level back in April to touching $7 since reporting in late August.The DNR Capital Australian Emerging Companies Fund currently holds a 6% position in Nanosonics.
Read MoreThe share price has rallied over 30% in the last month and Morgans downgrades to Hold from Add. Second half operating earnings (EBITDA) are forecast to be less than the first half so, potentially, some weakness is likely to follow when the company reports in late August.
Read Moretrophon’s high-frequency ultrasonic vibrations generate a sonically activated, supercharged hydrogen peroxide (H2O2) mist that kills bacteria, fungi and viruses.
Read MoreTap into trophon2 the latest innovation in automated ultrasound probe high-level disinfection. Easy to Set up, Simple to Use that delivers fast and efficient workflows… so you have more time to focus on your patients.
Read MoreDNR Capital’s Sam Twidale shares some insights with Informed Investor about Sydney-based medical technology company Nanosonics (ASX: NAN).
Read MoreMedical device maker Nanosonics (NAN) may be a small Australian company, but it has high-powered support in rolling out its innovative disinfection technology.
Read More